Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

• Päätekijät: Thomas Bettuzzi (Tekijä), Hervé Bachelez (Tekijä), Marie Beylot-Barry (Tekijä), Hugo Arlégui (Tekijä), Carle Paul (Tekijä), Manuelle Viguier (Tekijä), Emmanuel Mahé (Tekijä), Nathalie Beneton (Tekijä), Denis Jullien (Tekijä), Marie-Aleth Richard (Tekijä), Pascal Joly (Tekijä), Florence Tubach (Tekijä), Alain Dupuy (Tekijä), Emilie Sbidian (Tekijä), Olivier Chosidow (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Medical Journals Sweden, 2022-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (...